Twist Bioscience CorpTWST

Twist Bioscience Corp Fair Value Disclosure

10-KFiled Nov 17, 20252 min read
Fair Value Measurement
The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
Level 1—Quoted prices in active markets for identical assets or liabilities.
Level 2—Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considering counterparty credit risk in its assessment of fair value.
Assets Measured at Fair Value on a Recurring Basis
As of September 30, 2025, financial assets measured and recognized at fair value are as follows:

(in thousands) Level 1 Level 2 Level 3 Fair value
Assets
Money market funds$150,372$—$—$150,372
U.S. government treasury bills49,385——49,385
Total financial assets$199,757$—$—$199,757
As of September 30, 2024, financial assets measured and recognized at fair value are as follows:
(in thousands)Level 1Level 2Level 3Fair value
Assets
Money market funds$199,858 $— $— $199,858 
U.S. government treasury bills50,083 — — 50,083 
Total financial assets$249,941 $— $— $249,941 
Contractual maturities of short-term investments, as of September 30, 2025, were less than 12 months. The Company does not intend to sell the money market funds and short term investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis.
As of September 30, 2025 and 2024, there are no financial liabilities measured and recognized at fair value.
Free Sentinel

Want the next Twist Bioscience Corp fair value disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment Twist Bioscience Corp's next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Nov 17, 2025Showing above
2024Nov 18, 2024
2023Nov 21, 2023
2022Nov 28, 2022
2021Nov 23, 2021
2020Nov 27, 2020
2019Dec 13, 2019

About Fair Value Disclosures

Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.

Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.

Other Available Disclosures

Income TaxesRevenueGoodwill & IntangiblesLeasesSegmentsDebtCommitmentsNew StandardsPay vs Performance